Pseudomonas.indd

PSEUDOMONAS-CF-IgG
■ Surveillance of CF patients
I N S T I T U T
■ Detects chronic infection
prevention and controlof infectious diseasesand congenital disorders ■ Guides antibiotic therapy
■ Improves management of infections
O
R
IN VITRO DIAGNOSTIC USE
Statens Serum InstitutSSI Diagnostica2 Herredsvejen3400 HillerødDenmark Tel.: +45 3268 8378Fax: +45 3268 [email protected] Description
status of the patient for absorption of possible cross- Pseudomonas-CF-IgG antigen and standard control reactive antibodies. E-mail: [email protected] for serum is used for the quantitative measurement of the antibody level of Pseudomonas aeruginosa in human serum samples.
Storage and Shelf Life
Store the sealed vial of lyophilized Pseudomonas-CF-
The Pseudomonas-CF-IgG antigen is supplied as a 9 IgG antigen at room temperature. Expiry date of the mg lyophilized antigen obtained by sonication of the sealed vial is printed on the package. Dissolved antigen 17 most common P. aeruginosa serotypes. More than 64 can be frozen at -20oC and refrozen for at least 20 times different antigens are detectable in the antigen pool. without any change of activity. Pseudomonas-CF-IgG Pseudomonas-CF-IgG standard control serum is sup- standard control serum can be stored at -20oC.
plied in 1 ml and contains high titer antibodies directed against P. aeruginosa.
Available Products
One quantity of Pseudomonas-CF-IgG antigen and ■ Pseudomonas-CF-IgG antigen pool, lyophilized, 9 mg standard control serum allows for 100 ELISA tests. ■ Pseudomonas-CF-IgG standard control serum, 1 ml Background
P. aeruginosa is the most important bacterial patho- gen in patients with cystic fibrosis. Chronic pulmonary Information and Ordering
infection with P. aeruginosa is responsible for most of the morbidity and mortality in cystic fibrosis.
Diagnostics Sales and Marketing2 Herredsvejen Chronic P. aeruginosa infection can be discriminated from intermittent colonization by measuring serum IgG antibodies against P. aeruginosa. During the chro- nic infection a pronounced and increasing antibody response develops whereas this is not the case in inter- mittently colonized patients. The level of the antibody response in chronically infected patients correlates to the severity of the infection.
References
Høiby N et al: Eradication of early Pseudomonas aeruginosa infection. J
Cystic Fibrosis 4:49-54; 2005.
Since cystic fibrosis patients may experience repeated Döring G & Høiby N for the consensus study group: Early intervention intermittent P. aeruginosa colonization, they will be and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis 3:67-91; 2004.
subject to repeated courses of antibiotic therapy. Johansen H K et al: Antibody response to Pseudomonas aeruginosa in Measurements of the antibody response in such cases cystic fibrosis patients - a marker of therapeutic success? -A 30-year cohort study of survival in Danish CF patients after onset of chronic P. can be helpful in the management of the infection.
aeruginosa lung infection. Pediat Pulmonol 37:427-432; 2004.
Frederiksen B et al: Changing epidemiology of Pseudomonas aerugi- Principle
nosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 28:159-66; 1999.
The Pseudomonas-CF-IgG antigen is used as a coating Frederiksen B et al: Antibiotic treatment at time of initial colonization agent in a traditional ELISA setup. Pseudomonas-CF- with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function in patients with cystic fibrosis. IgG standard control serum is used to construct a stan- dard curve for calibration of a local standard serum. Frederiksen B et al: Improved survival in the Danish cystic fibrosis cen-tre - results of aggressive treatment. Pediatric Pulmonology 21:153-158, Lyophilized Pseudomonas-CF-IgG antigen is recon- stituted with sterile water and coated to ELISA plates. Valerius N H et al: Prevention of chronic colonization with Pseudomo-nas aeruginosa in patients with Cystic Fibrosis by early treatment with Patient serum, standard control serum and afterwards Ciprofloxacin and inhalation with Colistin. Lancet 338:725-26; 1991.
secondary antibody are added. Absorbance is read after Pressler T et al: IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by 2O2 addition. The absorbance of the standard control ELISA. Clin Exp Immunol 81:428-434; 1990.
serum dilutions is used to construct a standard curve. Høiby N et al: Taxonomic application of crossed immunoelectrophoresis. The absorbance of the patient sample is extrapolated Internat J Syst Bacteriol 37:229-240; 1987.
Pedersen S S et al: Diagnosis of chronic Pseudomonas aeruginosa infec- on the human standard curve and divided by 10.
tion in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 25:1830-1836; 1987.
Høiby N et al: Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa pre- Sera producing unexplainable results may be sent cipitins determined by means of crossed immunoelectrophoresis. Scand to the Reference Laboratory at the Department of Clinical Microbiology & Danish Cystic Fibrosis Centre, Rigshospitalet, University of Copenhagen, Denmark together with information about the bacteriological

Source: http://www.pharmaconsulting.ch/beilagen/Flyer%20Pseudomonas.pdf